Humacyte ( (HUMA) ) has shared an announcement.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Humacyte, Inc. has initiated a registered direct offering of approximately $30.0 million in common stock and warrants to an institutional investor. The offering includes over 5.6 million shares and equal warrants, with an exercise price of $5.28 each. The warrants are immediately exercisable with varying expiration periods. The transaction, facilitated by EF Hutton LLC as the placement agent, is expected to close by October 7, 2024, and is part of a previously declared effective shelf registration. The funds raised will support Humacyte’s mission to develop bioengineered human tissue for medical applications.
Find detailed analytics on HUMA stock on TipRanks’ Stock Analysis page.